Myriad Says It's Immune From Ambry's Antitrust Claims
Myriad Genetics Inc. told a federal court Monday that Ambry Genetics Corp.'s claim that Myriad is using a patent suit against it to monopolize the market for breast cancer gene tests...To view the full article, register now.
Already a subscriber? Click here to view full article